Logo

Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Share this

Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Shots:

  • The approval is based on P-III ARAMIS study assessing Nubeqa (600mg- qd) + ADT vs PBO + ADT in 1-509 patients in a ratio (2:1) with nmCRPC
  • The P-III ARAMIS study results: improvement in 1EPs of MFS (40.4mos. vs 18.4mos.); MFS is supported by delay in time to pain progression and other 2EPs i.e- time to cytotoxic CT- time to SSE
  • Nubeqa is an Ari- co-developed by Bayer and Orion Corporation- being evaluated in P-III ARASENS study for m-hormone-sensitive PC and an approved therapy in the US and Brazil and is underway in EU and other regions

Click here ­to­ read full press release/ article | Ref: Bayer | Image: BioSpace


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions